AI
Friday, November 10, 2023 3:05:37 PM
REPORT #44 (2023) For Week Ending 11/03/2023.
Thanks once again to @rafunrafun for providing the script data.
The Takeaway:
• All products down this week especially generic VASCEPA (Hikma -3.56%, ApoTex -5.23%, NorthStar -8.58% (Slide #3)
• Market share for VASCEPA® vs. generic VASCEPA® (57.13% vs. 42.87%) Slide #8
• VASCEPA® vs. Generic Lovaza (47.55% vs. 52.45%) Slide #7
• Total Market down from 177k to 174k, V+GV down to 106k from 108k. (Slide#2)
• VASCEPA still trending up while generic VASCEPA is trending down (Slide#2)
You may view the full report for WE 11/03/23 here:
https://drive.google.com/file/d/1H8QRbOVhSe6RHrw9gOGj7gaypWMoZt51/view?usp=sharing
Recent AMRN News
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
